GE HealthCare beats quarterly profit estimates on strong imaging demand, tariff refunds

Reuters

Wed, July 29, 2026 astatine 6:13 AM CDT 2 min read

July 29 (Reuters) - GE HealthCare connected Wednesday bushed Wall Street estimates for second-quarter profit, helped by beardown request for its ‌diagnostic and imaging devices and refunds of tariffs imposed nether U.S. ‌President Donald Trump.

Shares of the aesculapian instrumentality shaper roseate 12% successful premarket trading.

Investors are ​closely watching aesculapian instrumentality makers aft infirmary relation HCA Healthcare warned earlier this period astir softer request for surgical procedures and a emergence successful uninsured patients. Many Americans person dropped disconnected Affordable Care Act plans aft pandemic-era ‌subsidies expired.

However, different aesculapian ⁠device makers similar Abbott and Intuitive Surgical besides bushed second-quarter results' estimates, portion Johnson & Johnson did not emblem immoderate ⁠weakness successful process volumes.

GE HealthCare maintained its yearly nett forecast earlier this period erstwhile it besides provided immoderate preliminary second-quarter results.

The institution reported quarterly ​net income ​of $561 million, supra $486 cardinal past year, ​boosted by $129 cardinal successful tariff ‌refunds.

Companies are seeking to retrieve the tariffs they person paid aft courts recovered duties imposed by Trump past twelvemonth were collected illegally and indispensable beryllium repaid.

GE HealthCare besides said its adjusted halfway borderline was 40 ground points little than a twelvemonth ago, owed to ostentation related to representation ‌chips, lipid and freight costs.

"Global geopolitical ​instability, including the struggle successful the Middle ​East, adversely impacted our costs, ​supply chains, and logistics during the 2nd 4th of ‌2026," said the company.

The institution posted ​revenue of $5.30 cardinal ​for the 3 months ending June 30, compared with an estimated $5.26 billion. Sales grew 7.9% and 15.6% astatine its imaging instrumentality and ​pharmaceutical diagnostics segments, respectively.

It ‌reported quarterly adjusted net per stock of $1.13. Analysts connected mean ​estimated $1.04, according to information compiled by LSEG.

(Reporting by Puyaan Singh ​in Bengaluru; Editing by Joyjeet Das)